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INTRODUCTION
In the United States, approximately 17,000 people per year are diagnosed with brain
tumors, the leading cause of death from cancers in children ages 1-15 year (1,2). Gliomas
are the most prevalent type of brain tumors in adults, affecting 3.2/100,000 persons/yr in
the United States (www.CBTRUS.org). In spite of advances in surgery, chemotherapy,
and radiotherapy, the mean survival time of patients post-diagnosis remains approximately
9-12 months.
The nervous system is comprised of neurons supported and nourished by glial cells.
There are four different types of glial cells: astrocytes, oligodendroctyes, microglia, and
ependymal cells. Technically, a glioma is defined as "any neoplasm [an uncontrolled
growth of abnormal tissue] derived from one of the various types of cells that form the
interstitial tissue [glial cells] of the brain, spinal cord, pineal gland, posterior pituitary
gland, and retina"(3), and they can also be found in nasal lobes, peripheral, and cranial
nerves. In general, gliomas rarely metastasize beyond the central nervous system (CNS);
however, tumors from other parts of the body can metastasize to the CNS. Gliomas may be
found in many different regions of the CNS and are usually comprised of a heterogenous
cellular population.
There are many different types of gliomas each with its own characteristic features.
For example, there are brainstem gliomas, gigantocellular gliomas, mixed gliomas, nasal
gliomas, gliomas of the optic chasm, optic nerve gliomas, gliomas of the spinal cord,
telangiectactic gliomas (4). However, we will only discuss the main types: astrocytomas
and mixed gliomas. Astrocytomas are located anywhere in the CNS, grow slowly, are
invasive and are believed to originate from astrocytes. The most devastating type of
astrocytoma, grade-four astrocytoma, is more commonly known as glioblastoma
multiforme. It is located mostly in the cerebral hemisphere, is highly invasive,
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malignant, and probably originates from mature astrocytes. Glioblastomas are the most
cornmon type of brain tumors diagnosed in middle aged adults, accounting for about
30% of all primary brain tumors. They are the most malignant of all brain tumors and the
most difficult to treat with mean survival of less than 1 year following diagnosis (4).
Astrocytoma is also the most cornmon pediatric tumor diagnosed, accounting for just
over 50% of all newly diagnosed tumors in children (5). The diagnosis of gliomas
includes recognition of its symptoms, performing physical tests and assigning a grade to
the tumor. Symptoms of gliomas can include headaches (where pain increases especially
when one lies down), nausea, vomiting seizures, dizziness, personality changes, sudden
vision loss, memory loss, speech problems, sensory changes, mental impairment,
weakness, and perhaps paralysis (6). A physician may utilize CT scans, MRIs, EEGs,
X-rays, angiography, myelography, and/or a lumbar puncture to diagnose gliomas. If a
glioma is found, it is given a grade between one and four. A low grade glioma is a tumor
with a well-defined border that grows slowly. A mid or high grade number is assigned to
a tumor that grows more rapidly, is pathologically malignant and is difficult to remove
due to invasion in normal tissue. High grade tumors typically recur within 1-2 year
post treatment.
The current treatment for gliomas includes surgery, radiation, and chemotherapy.
The first step in treatment for a glioma is resection or biopsy. With resection, as much
of the tumor is removed as possible. A resection may also establish a pathological
diagnosis as the results from a biopsy might not be conclusive. Unfortunately, the lack
of a clearly defined tumor border makes it difficult to discem whether or not the entire
tumor was removed by resection. Also, if the glioma is close to critical areas within the
brain, there is a high risk of normal tissue damage during resections. In this case, partial
resections can be of some value. A partial resection can improve neurological functions,
relieve pressure, and increase tumor sensitivity to chemotherapeutic drugs. During
surgery, shunts may also be placed near the tumor to relieve pressure and to drain
excess fluid. A biopsy is useful when the tumor is inoperable and when imaging is
difficult. Another therapeutic option is radiation therapy (maximum dose of 60 Gy)
which is typically confined to tumor mass and 2 cm of surrounding tissue. Hyper-
fractionated radiation is an exposure to more frequent fractions of a smaller dose of
radiation over a smaller area of the brain. Stereotactic radiosurgery is an increased dose
of radiation to tumors less than 1.5 inches in diameter that minimizes exposure of
normal brain tissue by guiding the radiation with computer assisted imaging. In
interstital radiation therapy (brachytherapy), radioactive pellets are implanted in tumor
mass. Physicians also induce hyperthermia or use radiosensitizers, such as tirapazarnine,
to increase the response of a tumor to radiation. Chemotherapeutic drugs such
as carmustine, lomustine, procarbazine, and vincristine are administered in six week
cycles (6). The drawbacks of chemotherapy against brain tumors include the increase of
chemoresistant cells, inadequate drug delivery and the problems posed by the blood-
brain barrier resulting in only limited success, with an 80% relapse in glioblastoma
patients. In summary, current treatments for malignant or high-grade gliomas rarely
achieve long-term tumor control with frequent recurrence of the tumor (4,7) and death
quite probable in the near future for those patients diagnosed with gliomas. Therefore,
there is a critical need to develop novel therapeutic approaches to treat this devastating
cancer. Gene therapy constitutes a very attractive treatment option and in this chapter
will discuss some of the most promising gene therapeutic targets and precinical model
systems. We will also review the clincal implementation of these therapies in
GBM patients.
Castro et al. Gene Therapeutic Approaches to Brain Cancer 231
232 Castro et al.
including multi-drug resistant cancer cells. P53 overexpression increased the sensitivity of
drug and radiation resistant glioma cell lines to cisplatin and radiotherapy in vitro (15) and
adenovirus expressing p53 restored the sensitivity of9L glioblastoma cells to cisplatin (16)
and radiotherapy (17) in a rat model of glioblastoma. Overexpression of p53 using viral
vectors was also observed to improve survival in animal models inoculated with wild type
p53 expressing glioma cell lines, indicating a versatile function for this transgene in treating
all forms of glioma (18). Overexpression of p53 in cells increases the expression of
numerous apoptotic proteins including BAX activators, Bim, DP5, and the death receptor
ligand FasL. In a recent study, adenoviral vectors expressing p53 under the control of the
CMV promoter were demonstrated to induce significant levels of apoptosis as measured by
DNA fragmentation when injected intracranially into the tumor. Furthermore, a 100%
survival rate was observed in these animals 100 days following viral injection (19). The
success of these pre-clinical studies has led to Phase I clinical trials designed to assess the
toxicity of p53 gene therapy in human patients. The results of one trial have been recently
published to show the maximum tolerated dose was not reached and transgene expression
was evident in all patients in the nucleus of astrocytic tumor cells. Although expression was
limited to within 5 mm from the site of injection, it is hoped that higher doses of virus may
improve the distribution in subsequent studies (20).
A number of downstream pathways of p53 have also been tested and the
overexpression of two of these have shown promising results in controlling glioma in pre-
clinical animal models (21,22). Comparison between p53, p2I, and pI6-based therapies
suggests that vectors expressing p 16 and p2I are even more potent tumor suppressors than
p53 (23). However, these transgenes have not yet been tested in clinical models of glioma.
An alternative strategy was originally conceived by Bischoff JR and others, which
takes advantage of the anti-viral properties of p53. The human AdEIB gene is expressed
during adenovirus infection and codes for a 55 kDa protein that binds with and inacti-
vates p53. AdEIB is essential for a successful replication cycle within the host cell and
adenoviral vectors lacking the AdEIB gene are unable to replicate inside cells expressing
normal p53. These recombinant viral particles were cytopathic against p53-deficient human
tumor cell lines both in vitro and also in flank tumors in nude mice. Furthermore, these
viruses increased the efficacy of other viral vector therapies expressing cytotoxic transgene
products (24,25). In a recent report, combined therapy using this virus and conventional
radiotherapy was significantly more effective than either therapy alone in improving the
long term survival of nude mice with both p53 positive and p53 negative glioma (26). These
results highlight a common trend with viral vectors as useful therapies when combined with
more conventional chemotherapy or radiotherapy.
P16/Rb/CyclinD/CDK4 Pathway
The p16/Rb/cyclinD/CDK4 pathway is the most frequently mutated pathway in glioma,
and its mutations generally characterize a transition from low-grade tumors with relatively
slow rate of proliferation to intermediate-grade gliomas with dramatically increased cell
proliferation (27). In normal quiescent cells, Rb is present in a hypophosphorylated form
and is bound by the transcription factor E2Fl. This prevents transcription of genes
important for mitosis and prevents progression of the cell cycle through the G liS phase
restriction point (28). In general, mutations targeting the Rb pathway often inactivate Rb
directly through decreased affinity for E2F1 or reduced expression. Alternatively,
mutations that induce constitutive phosphorylation of Rb by CDK2, CDK4 or CDK6
can all contribute to reducing the affinity of Rb for E2F1 and subsequent increases
in proliferation (28). In gliomagenesis, allelic losses on chromosome 9q or 13q, or
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amplification of 12q usually accompany transition of glioma from low grade to
intennediate grade (29,30). This was later found to correspond with loss of Rb (13qI4)
loss of INK4A and ARF (9p21), or amplification of CDK4 (12qI3-14). Adenovirus
mediated Rb gene therapy has been successfully used in pre-clinical models of various
cancers including bladder cancer, where constitutively active truncated Rb delivered by
adenovirus produced marked growth inhibition, cytotoxicity, caspase-dependent
apoptosis, and G2/M block in the human RB-negative, telomerase-positive bladder
cancer cell line UM-UCI4 (31). In an animal model, Rb was found to decrease the
proliferation of spontaneous pituitary tumors in Rb +/- mice and prolonged survival of
animals (32). In a similar strategy to the oncolytic virus targeting p53, recombinant
adenovirus lacking AdElA (Delta24) can only replicate in cells expressing phospho-RB
and is preferentially cytotoxic to glioma cells. A single injection of Delta24 reduced
growth of flank tumors by 66%, and multiple injections reduced tumor growth by
84% (33). These data clearly highlight the fundamental role played by Rb in pathogenesis
of glioma.
More recently, substantial research has also investigated the potential of Rb
regulators and effectors in treating glioma. In particular, therapies that target pl6INK4A
have successfully reduced tumor proliferation and improved survival in rodent models of
glioma. Pl6INK4A r~duces Rb phosphorylation by inhibiting CDK4 and CDK6 activity and
is the most frequently mutated gene in human cancer after p53 and is mutated in more than
50% of glioblastomas (34). Initial in vitro experiments demonstrated that adenoviral
vectors expressing pl6INK4A induced cell cycle arrest of glioma cell lines (35). Results
in vivo corroborated these initial observations and pl6INK4A delivery was demonstrated to
improve survival in animal models of glioma, even when compared with p53 expressing
vectors (23).
In spite of these promising results, caution is warranted with all therapies designed
to repair common genetic lesions in glioma. In a recent report, p 16INK4A was expressed in
glioma cell lines under the control of the Tet repressor system (36). Elevated pl6INK4A
reduced tumor proliferation in vivo initially, supporting work published by others (36).
However, long tenn transgene expression induced a decrease in the expression of Rb
suggesting that gene therapy approaches involving pl6INK4A may ultimately lrad to the
selection of Rb deficient tumors (36). In fact, this is a potential problem of all approaches
designed to correct genetic lesions in cancer. Tumor cells are genetically unstable and
undergo accelerating genetic mutation. Unfortunately, this accelerates natural selection
and will select for tumor cells that overcome this transgene insertion. The possibility of
tumor cells compensating for transgene insertion through one or more subsequent
mutations must be explored in all promising therapies that repair the primary genetic
lesion in cancer.
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Suppressing Angiogenesis
Microscopic tumors are composed of populations of cells with altered characteristics to
the surrounding tissue that contribute to growth factor independence and elevated rates of
proliferation. In tumors, the rate of proliferation exceeds the rate of cell death and tumors
increase in size. Oxygen and nutrients required to fuel this expansion in tumor volume are
scavenged from surrounding tissue vasculature. However, diffusion of oxygen and
nutrients from neovascularure limits the absolute size of the tumor to about 2 mm3.
Angiogenesis is required to supply sufficient oxygen and nutrients to sustain further
growth. Angiogenesis involves the rapid proliferation of endothelial vascular cells and is
tightly regulated in adults. This regulation is coordinated by the expression of activators
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and inhibitors of angiogenesis. Tumors that acquire the ability to alter the expression of
promoters or inhibitors of angiogenesis timulate the development of new vasculature and
subsequently increase in size. In fact, promotion of angiogenesis appears to be a critical
step in the progression of glioma from a benign, microscopic lesion to a malignant
macroscopic cancer (37). Consequently, angiogenesis has received much attention as a
target of potential therapies. Angiogenesis in adult humans usually only occurs in response
to pathophysiological stimuli from wounds or hypoxia and angiogenic inhibitors generally
have few side effects (38). Several of these angiogenic inhibitors have been shown to
reduce tumor growth in vitro and in vivo and of these, thalidomide has been most
successfully used to treat glioma to date (39-42). However, a number of disadvantages
limit the potential of angiogenic inhibitors in clinical setting. Firstly, production of
sufficient quantities of angiogenic inhibitors is problematic and has limited the availability
of these drugs in clinical trials. Synthetic small molecule inhibitors of angiogenesis are
being developed to overcome this problem but the side effects of these drugs are currently
unknown. Secondly, angiogenic inhibitors are believed to be cytostatic, not cytotoxic and
this requires long-term treatment strategies to control and ultimately reduce tumor size.
Thirdly, toxic side effects have been observed with systemic delivery of some angiogenic
inhibitors (43). Gene therapy offers distinct advantages over conventional chemotherapy
in the safe delivery of clinically effective doses of angiogenic inhibitors to the tumor and
has been successfully employed in the treatment of a variety of tumors in preclinical
studies (44). This section will explore the various strategies employed by gene therapy in
treating brain tumors targeting both promoters and inhibitors of angiogenesis.
Promoters of Angiogenesis
The first growth factor identified as a positive regulator of angiogenesis was basic
fibroblast growth factor (bFGF) (45). Glioblastoma is among the most highly vascularized
of all tumors and increased expression of bFGF correlates with progression of a wide
variety of solid tumors (46). Adenoviral gene transfer of bFGF was found to promote
angiogenesis in rat brains (47). However, a clear correlation between increased bFGF
expression and glioma progression has not been demonstrated in glioma suggesting that
bFGF is not the principle mediator of angiogenesis (48). Another promoter of
angiogenesis called vascular endothelial growth factor (VEGF) was found to be
overexpressed in high grade gliomas (49). Expression of the receptors for VEGF, Flt-l
(VEGFR-I) and Flk-l (VEGFR-2), are also elevated in glioblastoma in comparison with
surrounding normal tissue and Flk-l in particular is believed to promote angiogenesis in
response to VEGF (50). VEGF was one of the first proteins identified to playa key role in
angiogenesis (51,52) and has since been the target of numerous gene therapy strategies
designed to reduce tumor burden. Early studies utilized anti-sense RNA to reduce
expression of VEGF in tumor cells. It was found that transfection of anti-sense VEGF
cDNA into rat glioma C6 cells in vitro impaired C6 tumor cells growth in vivo when
implanted into nude mice (53). More recently, recombinant virus has been used as a
vehicle for the transfer of antisense sequences in pre-clinical models of brain tumors.
Retroyirus encoding antisense VEGF cDNA sequence showed a statistically significant
improvement in survival of rats with intracranial neoplasms (54). An alternative strategy
for interfering with VEGF function has also been explored. A VEGF-R2 mutant has been
constructed that lacks normal kinase activity. This receptor displays dominant negative
function when overexpressed in cells that also express the wild type VEGF-R2 and a
retrovirus encoding this mutant VEGF2 receptor successfully prolonged survival of rats
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with intracranial tumors. These tumors displayed many classical signs of impaired
angiogenesis including reduced vascular density and elevated necrosis (55).~xpression of
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Inhibitors of Angiogenesis
The relatively low percentage of cells transduced by recombinant viral vectors is a limiting
factor in reducing promoters of angiogenesis, and indeed in every gene therapy strategy
that aims to reduce the expression or activity of target proteins. Inhibitors of angiogenesis
overcome this problem and have been the subject of numerous pre-clinical studies. Many
naturally occurring inhibitors of angiogenesis are derived from proteolytic degradation of
the extracellular matrix. Endostatin and angiostatin are generated following the proteolytic
cleavage of plasminogen and collagen respectively and are potent inhibitors of
angiogenesis (56,57). These peptides are difficult to generate in sufficient quantities
in vitro and are ideal candidates as transgenes for gene therapy. Recombinant viral vectors
that express endostatin (58,59) or angiostatin (60,61) have been developed and tested in
preclinical models of glioma. Improved survival of animals with intracranial neoplasms
was observed in all cases and tumor growth rates were reduced by as much as 90%. Other
anti-angiogenic protein fragments have also been studied for effectiveness in animal
models of glioma and these include soluble human platelet factor four and the N-terminal
fragment of rat prolactin. However, it appears that these transgenes are not as effective as
endostatin and angiostatin in significantly improving survival (62,63). A number of
proteins associated with immune system function have also anti-angiogenic properties.
IL-4 and Interferon gamma have been studied in rat models of glioma (64,65). Improved
survival and reduced angiogenesis and tumor growth rates were also observed in these
studies. However, the principle function of these trans genes is in recruiting and
modulating various cellular and humoral aspects of the immune response and will be dealt
with in the appropriate section.is was basic
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Activating the Immune Response
Histological analysis of tumors reveals that an immune response is often elicited against
the tumor. Inflammation, and even tum°.r-specific lymphocytes are often evident, and in
some rare cases, tumor regression spontaneously occurs in response to autoimmune
paraneoplastic syndromes (66,67). This is believed to be caused by tumor specific antigen
expression and underscores a role for the immune system in cancer immunosurveillance
and control of disease. Unfortunately, most tumors develop countermeasures that hamper
an effective immune response developing against he growing tumor. In pancreatic j3-cell
tumors for example, it has been demonstrated that the immune system was incapable of
either developing or maintaining an effective anti-immune response (68,69). More recent
studies in sarcoma suggest that tumor antigens fail to reach the lymph nodes and
consequently an effective cytotoxic T lymphocyte response is not evident (70).
Consequently, there is significant interest in developing an immunotherapy to improve
the response of the immune system to the tumor. Since the immunosuppression state
associated with gliomas appears to be mediated by an increase in autocrine secretion of
transforming growth factor-beta (TGP-beta), a TGP-beta inhibitor, decorin has been
delivered to intracranial CNS-l gliomas in vivo using adenoviral vectors, which
prolonged the survival of experimental tumor bearing rats, slowing glioma progression
(71). Recent progress in understanding the mechanisms of an immune response has led to
a renaissance in immunotherapy and over 100 Phase II clinical trials studying the
effectiveness of various cancer vaccines are currently underway in the United States.
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Many of these are already showing promising results with minor, limited side effects (73).
Gene therapy offers numerous different mechanisms to stimulate an immune response
against the proliferating tumor. We shall briefly outline progress in the four most
promising mechanisms below.
Tumor Antigen Delivered Through Adenoviral Transgene Expression
Most if not all tumors express proteins that are recognized by the immune system and are
called tumor antigens. Adenoviral vectors can be engineered to express these antigens as
trans genes and subsequently used to prime an immune response against that target antigen
if injected systemically. Promising results from preclinical trials have been reported for
renal cell carcinoma among others, where adenovirus expresses the tumor antigen
carbonic anhydrase IX protein (73). However, it is unclear whether this approach would be
effective reducing glioma in an immune-privileged organ as the brain.
Enhancement of the Anti-Tumor Immune Response Using Cytokines
Cytokines are a diverse collection of secreted and membrane bound proteins involved in
immunity and inflammation. Interferon j3, an immunomodulatory and anti-tumor cytokine
has been demonstrated to provide systemic anti-tumor immunity against GL261 cells
when delivered intracranially in lysosomes. This cytokine reduces tumor growth and
improves survival in C57/BL6 mice through a combination of anti-proliferative effects and
also activation of CD8 + but not CD4 + cells (74). In another report, tumor growth was
suppressed when mice were treated with a combination of IFN-j3 gene via cationic
liposomes and dendritic cells. This was mediated by a highly effective cytotoxic
lymphocyte (CTL) response against the tumor and was far more efficient that either
therapy alone (75). Adeno-associated virus designed to deliver the transgene IFNj3 has
also been developed and completely inhibits growth of exogenous human tumor
xenografts when delivered intratumorally in nude mice, further supporting the potential of
1FN-j3 as a novel therapy for treating human glioma (76). Phase I clinical trials have
recently begun using a replication deficient adenovirus expressing 1FN-j3 in human
subjects with the primary aim of assessing the maximum tolerated dose (77).
Enhancing T-Cell Activation
A number of cytokines are believed to activate various subclasses of T lymphocytes. For
example, IL-12 is required for anti-tumor THl type pattern of differentiation in naIve
mature T lymphocytes. An adenovirus expressing the transgene IL-12 has been reported to
enhance the immune response against brain tumors and improve survival in mice
inoculated with GL26 glioma cells intracranially. At the tumor site an increased number of
CD4 + and CDS+T cells were identified (7S). Recently, allogenic cells genetically
engineered to secrete IL-2 were found to significantly improve survival in a mouse glioma
carcinoma model. The immune response was found to be predominantly mediated by
CDS + and natural killer cells (NK) and was highly specific for the glioma cells above non-
neoplastic cells (79).
Enhancing Dendritic Cells Activation
It is believed that dendritic cells are the principle antigen presenting cells of the immune
system and are required for the development of an antigen-dependent immune response.
However, dendritic cells are absent from the brain except under conditions of
inflammation and it is believed that this is a major reason behind immune privilege in
lstro et al. Gene Therapeutic Approaches to Brain Cancer 237
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the brain (80-85). Dendritic cells differentiate from precursor cells in response to Flt3L
through a STAT3 dependent mechanism (86). Expression of Flt3L by daily administration
of purified, recombinant Flt3L has been demonstrated to induce complete tumor
regression and significantly improve survival (87). Furthermore, dendritic cells are highly
effective inducers of tumor specific killer and helper T lymphocyte generation in animal
models of tumors (88). Therefore, a lot of interest has been generated recently surrounding
the use of dendritic cells and Flt3L in immunotherapy. The use of dendritic cell based
vaccines is currently ongoing in about 20 Phase n and at least one Phase ill clinical trial in
the U.S.A., many of which are showing promising results. In addition, early studies have
indicated that toxicity of dendritic cell vaccination is mild and limited to local reactions at
the site of injection (72). In a stringent glioma model, in which RAdTK/ganciclovir
administration is ineffective, we have demonstrated that recombinant adenovirus
expressing RAdFlt3L eliminates intracranial neoplasms and significantly improves
survival when co-delivered with the tumoricidal agent RAdTK/ganciclovir (89,90).
This data highlight the promise of immunotherapies in greatly enhancing the efficacy of
current therapies and the potential of curing glioma.
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Harnessing Death Receptor Ligand Interactions
Apoptosis, also known as programmed cell death, is a universal feature of multi-cellular
eukaryotes and plays a fundamental role in controlling many diverse physiological
processes including tissue sculpting during development and tissue homeostasis in adults.
Defects in apoptosis are responsible for numerous pathologies including tumor initiation
and progression (91,92). For these reasons, apoptosis is tightly regulated and studies in
vertebrates have identified a number of signal transduction pathways that can either induce
or inhibit apoptosis. A number of studies have investigated the potential selectively
activate tumor cell death by inducing pro-apototic genes using gene therapy (93). In
particular, focus has centered on components of a family of receptors called
death receptors.
Death receptors are present on the plasma membrane and their activation can induce
apoptosis in cells following engagement of receptors with extracellular ligands. In
mammals, death receptors belong to a large family of membrane bound receptors called
the tumor necrosis factor receptor superfamily (TNFRSF), which include at least nine
death receptors. TNFRSF members regulate various aspects of cell proliferation,
differentiation, and apoptosis and all members of this family contain between one and
four short cysteine-rich extracellular domains. These repeats usually contain six conserved
cysteine residues that form three disulphide bonds and these subdomains adopt conserved
tertiary folds. It is believed that the order of cysteine rich repeats determines the affinity
and specificity of receptor for ligand. The ligands that bind with these receptors belong to
another large family of transmembrane proteins called the tumor necrosis factor
superfamily. Ligands bind with receptors and induce trimerisation of receptors at the
plasma membrane, which in turn permits the recruitment of initiator caspases to the death
domain, propagating the apoptosis inducing signal transduction cascades (94,95). Initiator
procaspases cleave effector caspase which, once activated, inactivate target proteins and
thereby promoting the ordered degradation of nucleic acids, enzymes, and structural
proteins (96).
The Fas receptor is perhaps the most widely studied death receptor and ligand
system. Viral vectors expressing Fas ligand have been demonstrated to possess potent anti-
glioma activity both in vitro and in vivo (97-99). Furthermore, these vectors enhance the
anti-tumor activity of virus expressing p53 and Thymidine kinase (TK) (100,101). TRAIL,
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the ligand for TRAILRI arid TRAILR2, has also been assessed as a potential therapeutic
trans gene for gene therapy. The anti-tumor activity of recombinant virus expressing
TRAIL is more controversial, although this transgene is not effective alone in glioma cell
lines (102), co-delivery of TRAIL and Fas ligand expressing viral vectors enhances
apoptosis induction compared to either virus alone (103).10 addition, intracranial injection
of virus expressing TRAIL significantly improves survival in a rat model of glioma (104).
Providing Drug Resistance to Hematopoietic Cells
Gene therapy vectors can not only be used to kill tumoral cells, but also be engineered
to confer survival advantages on normal cells. A limiting factor with conventional
radiotherapy and chemotherapy is the toxicity to normal cells. Many of these therapies are
toxic to proliferating cells, including but not limited to tumor cells, and relatively non-toxic
to non-proliferating cells. Although the majority of cells in adults are non-proliferating, a
small but important proportion of these are rapidly dividing. Hematopoietic stem cells
are rapidly dividing cells that are often decimated in response to radiotherapy and
chemotherapy. Bone marrow transplants are often required, increasing the risk of anemia,
infection, and further complications in cancer patients. Stem cells can be transduced in vitro
where drug resistant stem cells can be selected and amplified in vivo (105). A number of
Phase I clinical trials have been undertaken with various chemotherapy drug resistant genes
including 0-6-methylguanine-DNA methyltransferase gene and MDR-l (106). Although
many of these approaches have not been very successful, in part due to poor transduction
efficiencies, recent improvements in vector design may increase the efficacy of these agents
in promoting drug resistance in vivo (107). Many of these vectors are retroviral in origin and
may result in the accidental transfer of the drug resistance gene to cancer cells via retroviral
integration into cancer genomes. Therefore safety checks including replication deficiency
and inefficient repackaging of the multi-drug resistance gene are also being developed in
these vectors.
Enzyme/Prodrug Gene Therapy
While radiotherapy and surgery succeed in treating confined malignancies, the majority of
cancers require systemic therapies that target tumor cells but, unfortunately their low
specificity also produces toxicity to normal cells. Current research is attempting to identify
more specific ways to directly target tumor cells and reduce treatment toxicity to normal
cells. The use of enzyme/prodrug combinations directly targeting therapeutics to the tumor
mass through the use of antibody or viral vectors has emerged as a potentially viable option.
Prodrugs are chemicals that are non-cytotoxic over a wide range of dosages however
upon conversion by a specific activating enzyme, become a toxic molecule capable of
triggering cell death. The ideal prodrug should (1) be freely diffusible throughout the
tumor (2) remain chemically stable under physiological conditions, (3) possess suitable
pharmacological and pharmacokinetic properties, (4) convert into a chemical that is at
least 100-fold more toxic than the prodrug, and (5) induce cytotoxicity that is cell cycle
phase independent. In addition to the prodrug characteristics, dynamics of the enzyme are
also crucial to successful cancer treatment. Ideal enzymes should be of low molecular
weight with high catalytic activity under physiological conditions such that even at low
concentrations of prodrug, efficient catalysis can occur. Expression of the enzyme should
not alone lead to cytotoxicity. Additionally the reaction pathway for conversion of the
prodrug into a toxin should be unique from pathways utilized by endogenous enzymes to
avoid cytotoxcicity in normal tissue (108).
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Initial investigations sought to exploit prodrug activation using endogenous
enzymes expressed at higher levels in tumor cells (109,110). However, clinical application
was limited since such enzymes were expressed in normal cells and only a small number of
human cancers had high enough levels of activating enzymes for efficacy. To overcome
these problems, identification of non-mammalian enzyme/prodrug combinations were
identified. Usage of antibodies and viral vectors to specifically target enzyme to tumor
tissue has produced promising results in vitro and in vivo.
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Antibody-Directed Enzyme Prodrug Therapy
Antibodies have been used to target tumor antigens or growth factors in attempts to
specifically deliver cytotoxic drugs, toxins, and radionucleotides (111,112). Likewise
conjugation of prodrugs to monoclonal antibodies may also be used for specific targeting
(113-115). In antibody-directed enzyme prodrug therapy (ADEPT); the catalytic enzyme
is covalently linked to an antibody, which recognizes tumor-specific antigen and binds to
this specific surface antigen, causing its internalization together with the activating
enzyme. Upon prodrug administration a large number of toxic molecules can be produced
in the local tumor area. Since internalization of the complex is not required for catalysis,
diffusion of the toxin into nearby tumor cells may result in tumor cell death. Likewise,
transfer of toxin after its internalization to adjacent cells via gap junctions further enhances
the bystander effect of ADEPT. In order to minimize death of normal cells, administration
of the enzyme used to convert the prodrug can be time delayed to allow removal of
unbound enzyme-antibody conjugates.
There are several disadvantages to ADEPT that limit its clinical applications. One
limitation is the low number of tumor-specific antigens that have been identified thus far
for use as targets; however ADEPT strategies have been used to treat colorectal, breast,
and choriocarcinoma tumors. In addition, most monoclonal antibodies are of murine origin
and elicit a significant immunogenic response in a human patient that requires use of
immunosuppressive drugs. Humanized antibodies have been constructed that retain the
mouse antibody determining region and its high affinity binding but within a human
antibody framework (116-118). Last, monoclonal antibodies are large molecular weight
molecules with slow rates of diffusion that may limit the total tumor area able to be treated
(119,120). Use of recombinant antibodies engineered to be smaller while retaining a high
specificity and affinity may overcome this limitation (121-126).
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Gene-Directed and Virus-Directed Enzyme Prod rug Therapy
To further extend ADEPT while overcoming some of its limitations, utilization of vectors
other than monoclonal antibodies were developed. Gene-directed enzyme prodrug therapy
(GDEPT) seeks to introduce a gene encoding a prodrug-activating enzyme directly into
tumor cells. Once inside the cell transcription of the gene produces an active but non-
cytotoxic enzyme. Upon systemic administration of the prodrug, cells transduced with the
enzyme will convert the prodrug into its toxic metabolite triggering cell death. For GDEPT
to be successful the enzyme must be expressed exclusively within the tumor cells and its
catalytic activity must be high enough compared to normal tissue for clinical benefit. Since
expression will not occur in all tumor cells, a significant bystander effect is essential in this
strategy. Bystander effects occur when the cytotoxic metabolite is transmitted to cells not
originally transduced with the enzyme. This may occur via transport through gap junctions
or by diffusion through the extracellular space. In addition to delivery of the enzyme,
administration of the prodrug must be delayed sufficiently to allow expression of the
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enzyme in target cells. The majority of GDEPT strategies have exploited viral-mediated
delivery systems. These systems exploit the ability of viruses to enter cells and express the
trans genes they carry. Use of viruses as the delivery agent has been termed virus directed
enzyme prodrug therapy or VDEPT.
Enzyme/Prodrug Combinations
A large number of enzyme/prodrug combinations have been discovered and characterized.
While the ideal characteristics for enzymes and prodrugs used in ADEPT/GDEPT
strategies was outlined above, none of the enzyme/prodrug combinations are perfect, each
has its advantages and disadvantages. The most well characterized enzyme/prodrug
combinations are herpes simplex virus type I -thymidine kinase (HSV1-TK)/ganciclovir
(GCV) and cytosine deaminase (CD)/ 5-tluorocytosine (5-FC). Each of these pairings has
been used in numerous gene therapy GDEPT clinical trials. The bacterial enzyme
carboxypeptidase G2 (CPG2)/CMDA is the only ADEPT combination to reach clinical
trial stage. In addition to these well characterized pairings E. coli guanine phosphoribosyl
transferase/6-thioxanthine, cytochrome P450/CPA, E. coli purine nucleoside phosphoryl-
ase/6-methyl-purine-2'-deoxynucleoside, E. coli nitroreductase/CB1954, cytochrome
P450 4B1/4-IM and 2AA, horseradish peroxidase/indole-3-acetic acid and carboxypepti-
dase/methotrexate-Cl-phenylalanine have all been under investigation (108,127).
Herpes Simplex Virus Type 1: Thymidine KinaselGanciclovir
HSVI-TK was first developed as a prodrug-activating enzyme by Moolten and has been
studied intensively in preclinical and clinical studies to treat a wide range of solid tumors
(128,129). HSVI-TK delivery to tumor cells has been accomplished using both adeno-
and retroviral vector systems (130-137). HSVI-TK is nearly l000-fold more efficient at
mono-phosphorylation of GCV than any mammalian HSVI-TK (138). GCV, acyclic
analog of the nucleoside 2-deoxyguanosine, is an anti-herpetic agent with a known
toxicity profile (138-141). When HSVI-TK phosphorylates GCV it is converted to
GCV -monophosphate that is further converted by other cellular kinases to di- and
triphosphorylated forms. GCV-triphosphate is the most toxic of these forms (138-141).
GCV -triphosphate is structurally similar to 2-deoxyguanosine triphosphate and thus can
be incorporated into DNA chains by DNA polymerase (138-141). GCV-triphosphate
may inhibit DNA polymerase or upon incorporation into the DNA chain, trigger chain
termination which induces cell death (139-141).
HSVI-TK/GCV pairing was the first ~ which bystander effects were described
(142). In murine glioma studies, total tumor regression was observed when only 10% of
tumor cells were transduced with HSVI-TK (130,142,143). HSVI-TK/GCVs bystander
effect requires cell to cell contact. GCV -triphosphates are highly charged molecules that
are insoluble in lipid membranes and thus cannot diffuse freely in the extracellular space.
Instead, GCV-triphosphates move between cells via gap junctions (144-147). In addition
to movement through gap junctions the bystander effect of HSVI-TK/GCV may be
enhanced by the host immune response to the tumor following treatment. Treatment was
observed to trigger infiltration of CD4 + and CD8 + T cells and macrophages as well as
increased expression of a host of cytokines (148). Induction of the immune system resulted
in tumor regression locally at the site of HSV 1- TK/GCV action and at distant sites in both
normal and immunocompromised animals (136,149-151).
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Based on positive preclinical tumor regression data, HSVI-TK/GCV studies have
been conducted as Phase I and Phase II clinical trials. In the initials trials undertaken,
survival of patients treated with HSV1- TK/GCV after surgical resection were similar to
patients who had not received the GDEPT therapy (152,153). Several theories exist for
the disparity between preclinical and clinical trial data. First, an insufficient number of
tumor cells may have been transduced for therapeutic benefit. Second, the growth rate
of the tumor-cells may play an important role in HSVI-TK/GCV action and would be
different between experimental tumors and those spontaneously arising in humans.
Third, the dosages of GCV used preclinically were much higher than those used in the
clinical trials indicating that the lack of GCV substrate may have precluded therapeutic
benefit. Increased tumor transduction efficiency, exploitation of bystander effects, and
further engineering of HSVI-TK to be more efficient and/or GCV to be less toxic will
be required for clinically relevant therapeutic benefits from HSV 1- TK/GCV
prodrug therapy.
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Cytosine Deaminase/5 -Fluorocytosine
As with HSV 1- TK, CD produces a toxic nucleotide analog that triggers cell death. CD
is an enzyme expressed in bacteria and fungi and absent in in mammalian cells
catalyzes the conversion of cytosine to uracil (154,155). When combined with the
prodrug 5-FC, deamination generates 5-fluorouracil (5-FU). CD/5-FD kills cells via both
proliferation-dependent and independent means. Metabolites of 5-FU cause cell death
through inhibition of thymidylate synthase, resulting in nicked DNA and inhibition of
RNA processing. CD/5-FC results in a strong bystander effect that, unlike HSVI-TK/
GCV, does not require cell to cell contact (156). Transduction of only 2-4% of cells
resulted in significant regression of tumor as toxic metabolites freely ditfuse cells
(157,158). This effect is not restricted to tumor cells and damage to normal tissue may
result. In addition to bystander effects caused by ditfusion of the toxin, as with HSV1-
TK, immune mediated bystander effects also occur as NK infiltrate tumors treated with
CD/5-FC therapy (159). The species of origin for CD may produce more catalytically
active forms as observed with S. cerevisiae CD compared to E. coli CD (160,161).
Currently Phase I trials of adenovirally delivered CD in patients with metastatic liver
disease are ongoing (162-164).
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Carboxypeptidase G2/4-Benzoyl-L-Glutamic Acid
CPG2 is found in bacteria but not humans and removes glutamic acid moieties from
folic acid, inhibiting cell growth. When combined with the prodrug 4-benzoyl-L-
glutamic acid (CMDA), a DNA-crosslinking mustard drug is released (165). Unlike
HSV1-TK and CD, catalysis of the prodrug with CPG2 does not require further
enzymatic processing to become the final toxic compound. Mustard-alkylating agents
are not cell-cycle dependent enabling the killing of proliferating and non-proliferating
cells (166). As with other enzyme/prodrugs, CPG2/CMDA produces a robust bystander
effect. Only 10-12% transduction resulted in 50-100% killing in vitro and in vivo
(167-169). Immune mediated bystander effects are currently unreported. CPG2/CMDA
was first used in ADEPT Phase I clinical trial and did not show toxicity related to the
enzyme or prodrug (162,163). GDEPT usages of CPG2 have not reached clinical trial
stage yet.
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Targeted Toxins for Glioma Therapy
Over the past several years, research efforts have focused on the utilization of cellular
I:eceptors exclusively over-expressed in brain tumor cells for targeted therapy. It has
been reported that human tumors, including established glioma cell lines, primary
glioblastoma cell cultures and surgical glioma biopsies express a variant of the IL-13
receptor. This receptor (ILI3Rcx2) is different from its physiological counterpart, i.e.,
IL13/1L4R (170-174). The urokinase-type plasminogen activator (uP A) receptor is also
overexpressed in glioblastomas (170-173,175), as well as receptors for growth factors,
such as epidennal growth factor (EGF) receptor (176,177). Importantly, since these
receptors are virtually absent in the nonnal brain, they are very attractive targets for
targeted therapeutic approaches in glioma, minimizing any putative adverse side effects
to nonnal brain tissue. Thus, ligands of these receptors, such as IL-13, uPA, EGF, and
transforming growth factor cx (TGF-cx) have been fused to the catalytic and
translocation domains of highly cytotoxic bacterial products, including Pseudomonas
(174,177,178) and Diphteria toxins (78,173,175,176), in order to selectively kill glioma
cells, but preserving surrounding nonnal brain tissue. These fusion toxins have shown
promising results in in vitro and in vivo experiments using murine glioma models and
cliniGal trials have shown that direct interstitial infusion can be used to successfully
distribute chimeric toxins in tumors in the CNS, achieving anti-tumor responses without
systemic toxicity in patients with malignant brain tumors (179). The chimeric toxin
composed of IL-13 and truncated Pseudomonas exotoxin, also tenDed IL-13 toxin, is
currently being used in several clinical trials that recruit patients throughout the country
as well as Canada, Gennany, Israel, and the Netherlands. The IL-13 toxin has been
shown to exert a potent cytotoxic effect in most human glioblastoma cells tested in
culture (174,178,180) and in vivo, in human xenografts consisting of glioma cells
implanted in the flank of nude mice (181). Moreover, the intratumoral administration of
ILI3-PE toXin into intracranial human glioma xenografts in mice showed highly
cytotoxic effects without undesirable side effects (182). To optimize the targeting of
GBM associated IL-13cx2 receptor, human IL-13 (hIL-13) gene has been engineered
leading to a mutated fonD of hIL-13 that exhibits 50 fold higher affinity for the IL-
13cx2 receptor present in human glioma cells when compared to the wild type IL-13
(183,184). Fusion of this muIL-13 to PE resulted in an even more active cytotoxin in
glioma tumors both in vitro and in vivo (183). Importantly, the muIL13 no longer
interacts with the principal chain of lIAR, thus becoming ineffective in its binding to
this receptor and signaling through the physiological IL13/1L4R of nonnal cells. This in
turn decreases the already low toxicity of the chimeric toXin to nonnal cells (183).
Thus, although this mutant has negligible affinity by IL-13 receptor of nonnal cells, it
exerts an enhanced cytotoxic effect towards glioma cells. We are currently developing a
gene therapy approach based on IL-13R-targeting, in which a high capacity adenoviral
vector encodes for muIL-13 fused to the truncated PE toxin and a mutated IL-4 that
functions as antagonist of the IL13R present in nonnal cells without interacting with
IL13cx2R for an enhanced safety profile (Fig. 1) (185). The fact that IL13Rcx2 is over
expressed not only in glioma cells, but also in other malignancies, including renal cell
carcinoma (186), ovarian carcinoma (187), colon adenocarcinoma (178), epidennoid
carcinoma (178), AIDS-associated Kaposi's sarcoma (188), prostate carcinoma (189)
and pancreatic cancer (190), makes IL13Rcx2 a unique target for anticancer therapy.
Gene therapy offers the possibility of making the targeted toxins approach more
efficacious and less toxic for GBM therapy, by expressing the genetically engineered
toxin under a regulatable promoter, within a viral vector, it would eliminate the need of
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Figure 1 Targeted toxins for glioma gene therapy. Structure of a high capacity adenoviral vectors
encoding mull.-13 fused to the truncated PE toxin, which binds and kills glioma cells without
affecting normal brain cells. For further safety, this vector includes a mutated IL-4 (muIL-4), which
functions as antagonist of the ILl3R present in nonnal cells, without interacting with IL13Ra2, thus
it prevents muIL-13-PE to interact with normal cells, protecting them from the detrimental effect of
the toxin, while it does not affect muIL-13-PE binding to glioma cells. Therapeutic trangenes are
encoded under the control of the TRE promoter, which is activated by a transactivator (rtT A2SM2)
only in the presence of the antibiotic doxycycline, further increasing the safety of this approach.
Abbreviations: PE, pseudomonas exotoxin; TRE, tetracycline response element.
repeated treatment due to the short half-life of the therapy, it will also allow the fine
regulation of the levels of toxin expressed in case the therapy is no longer needed or to
obviate adverse side effects.
VALIDATION OF CANCER GENE THERAPY STRATEGIES
IN VITRO AND IN VIVO
An Overview of Commonly Used Glioma Models
Accurate experimental models are of paramount importance in developing effective
therapies against diseases. A clinically relevant model helps establish the effectiveness of
new therapies, such as gene therapy in a pre-clinical setting. In addition, genetic, and
biochemical studies of these experimental models may shed light on defects that
contribute to the development of brain tumors in humans. Table 1 shows the requirements
that an ideal experimental model for glioma should meet (191).
Rodents are routinely used in preclinical studies of glioma and offer many
advantages over other vertebrate models, invertebrate models or cell culture models.
Unlike many larger mammals, mice, and rats have a high reproductive rate and are easy to
handle and maintain. In addition, mice, and rats have been extensively studied in scientific
literature and consequently have well-defined genetics, biochemistry, and physiology.
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Table 1 Features of Cell Implantation and Genetic Glioma Models
Desired features of glioma
animal models Cell implantation models Genetic models
0 0
0
:t 0
0
0
0
0
0 0
0
0
0
0
0
0
Fast
0
0
0
Slow
Glial origin
Biological similarity to human
gliomas
Hystological similarity to human
gliomas (invasion, neovasculari-
zation)
Intact tumor-host interactions
Allow detection of antitumoral
immune responses
Non-immunogenic in syngeneic
animals
Allow study of human glioma
tumors
Allow non-invasive techniques of
tumor progression diagnosis
Accurate knowledge of tumor
location
Predictable and reproducible tumor
growth rates
Similar time to death of animals
Enough survival time to test therapy
Tumor progression
Technically easy and not expensive
Available for rat and mice Only mice
Genomics has further endorsed the use of mice and rats as models for human disease. Most
human genes have homologues in rats and mice that share significant sequence homology
with their human counterparts. Moreover, the mouse genome is very pliable, and a large
number of genetically modified strains have been created, characterized, and maintained
either by selectively breeding mice with spontaneous genetic mutations or by using
transgenics. Transgenics in particular has established mice as the most commonly used
laboratory mammal for studying human disease. Transgenic rats have also been recently
created and as this technology progresses, the rat may offer attractive models for GBM
preclinical studies.
Early Models of Glioma
Prior to 1970, research in glioma was limited by the lack of suitable pre-clinical models to
design and test new therapies. DNA a1kylating agents, including N-methyl-N-nitrosourea
(NMU), generate point mutations in DNA and were found to promote gliomagenesis when
injected i.v. into rabbits (192). This observation quickly led to the development of rat
models of glioma involving repeated injection of NMU i.v. and subsequent observations
for neurological symptoms to appear (193). Although these models are labor intensive and
not particularly suited to pre-clinical studies, cell lines were developed from rats and mice
injected with NMU. Many of these cell lines grow in vitro and in vivo and quickly gave
~
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rise to a more versatile pre-clinical mbdel of glioma, using GBM cell lines to develop
implantation models in xenogeneic or syngeneic hosts.
Genetic models
0
0
Xenograft Models of Glioma
Many models of glioma currently inoculate mice and rats with exogenous glioma cell lines
grown in vitro; These cell lines can either be injected in the periphery giving rise to flank
tumors, or alternatively injected directly into the brain of animals. Injection of cells
directly into the brain requires a stereotactic device to ensure accurate and reproducible
results and is clinically more relevant than flank tumors. However, some experimental
designs require the convenient access of flank tumors and consequently researchers utilize
both models. In these cases, data should be corroborated using intracranial models to
account for differences in the extracellular environments. Exogenous glioma xenografts
offer several advantages over other glioma models including highly efficient
gliomagenesis, reproducible growth rates, similar time to death for different animals
and an accurate knowledge of the site of the tumor. This last point is particularly
advantageous in intracranial models of glioma where injection sites must be carefully
chosen to overlap with the site of the tumor. Furthermore, xenograft models of glioma
have been widely used and are well characterized in the literature. However, these models
also have a number of important limitations that must be considered when choosing a
suitable model for gliomagenesis. Paramount of these is that the majority of exogenous
glioma xenografts utilize cell lines originally derived from human glioma. Consequently,
immune rejection of the implanted tumor can alter the progression of the disease and
decrease the clinical accuracy of the model. To limit this problem, human GBM models
have been developed in immune-deficient mice and/or rats. Most models currently use cell
lines originally derived from the same animal strain; these syngeneic xenografts generally
have minimal non-specific immune reactivity. Another limiting factor with these models is
the absence of developing stages of glioma. Therefore, while these models are useful to
estimate the clinical effectiveness of various transgenes in gene therapy, they are not well
designed to understand initial events that occur during gliomagenesis. In addition,
promising results should be verified in more stringent models of glioma before progressing
to clinical trials in human patients.
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Rat Intracranial Glioma Cell Implantation Models
Intracranial injection of cell lines into rats has been used as to model glioma since the early
1970s (194). A wide diversity of cell lines have been developed for this purpose. Some of
the most widely used rat brain tumor models ihclude 9L gliosarcoma, CNS-1 glioma, C6
glioma, F98 glioma. RG2 glioma, and RT-2 induced glioma (195). The most widely used
intracranial glioma model has been the 9L gliosarcoma model. This model uses 9L
gliosarcoma cells originally derived from CD Fischer rats injected i.v. with
methylnitrosourea to promote spontaneous gliomagenesis. Early studies in gene therapy
primarily used this model and some spectacular results were observed (196), (Nam M,
Brain Res 1996). However, this model is highly immunogenic and it has since been
demonstrated that an immune response against the 9L gliosarcoma is the principal means
by .which non-transduced cells are killed by HSV1-TKIganciclover treatment.
Consequently this model is not optimal for studies involving gene therapy, especially
approaches that aim to harness immunotherapeutic targets (197,198). Another cell line
derived from rats injected with methylnitrosourea (MNU) (C6) was developed.
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Unfortunately, the C6 glioma cell line was originally developed in an outbred Wistar rat
and consequently there is no syngeneic host that can be used to propragate it.
Consequently, C6 is immunogenic in most hosts and like 9L gliosarcoma cells this
severely limits the usefulness of C6 glioma models in gene therapy (195). Recently, the
CNS-l glioma cell line was derived from an inbred Lewis rat that had been injected with
MNU in a similar fashion to both 9L and C6 glioma cells. However, unlike 9L cells the
CNS-l glioma stains positive for GFAP and S-I00. CNS-l cells have in vivo growth rates
and histology that more closely resemble human glioma than 9L cells. Furthermore, CNS-
I cells are not immunogenic in vivo in Lewis rats and therefore are ideally suited for
pre-clinical testing (Fig. 2) (199).
An alternative approach was utilized in the development of F98 and RG2 cell lines.
The mutagen of choice was not MNU but instead was ethylnitrosourea (ENU) in both
cases. Both of these glioma cell lines are non-immunogenic. F98 glioma cells were
originally from offspring of a pregnant CD Fisher rat and are remarkably similar to human
glioma in many ways. They are very weakly immunogenic, they display an infiltrative
pattern of growth similar to human glioma and as few as 10 cells invariably kill animals
when inoculated intracranially in vivo. RG2 cells were produced in a similar fashion and
are non-immunogenic in syngeneic Fischer rats (200). The invasive pattern of growth and
refractory nature to chemotherapeutic agents are advantages to using this model in
assessing the effectiveness of novel gene therapeutic agents.
Mouse Intracranial Glioma Cell Implantation Models
Historically, the rat was the rodent of choice for pre-clinical models of glioma due to its
larger size and well documented physiology and anatomy. However, in the genomic era
with the advent of transgenics, the mouse has superseded the rat as the most popular model
of human diseases. Many of these models seek to explore the early events of gliomagenesis
by mutating key regulatory genes using transgenics and in doing so develop more accurate
Figure 2 (See color insert) CNS-l tumor histology. 5000 CNS-l glioma cells were implanted in
the striatum of syngeneic Lewis rats. Animals become moribund within 3 weeks of implantation. (A)
Nissl staining of a brain section showing a CNS-l tumor from an untreated moribund animal. Note
areas of infiltration (arrows). (B) Hematoxilin/eosin stained brain section showing a CNS-l tumor
from an untreated moribund animal. The arrow indicates an area of cell death within the tumor. (C)
Nissl stained brain section showing areas of tumoral cell infiltration in the same animal pictured in A.
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pre-clinical models of human glioma. Also number of intracranial xenograft models have
also been developed to accelerate the discovery of novel promising therapies. Unfortunately
many of the earlier models often used human glioma xenografts (i.e., SF-90295, U-25 1 or
D54) or rat glioma xenografts (primarily C6) transplanted into immunocompromised mice.
Immune-mediated events before, during, and after therapy cannot be observed in these
models, limiting their usefulness. A number of syngeneic models have been developed. The
first model used was glioma 26 (GL-26). These cells were found to be non-immunogenic
when injected either subcutaneously or intracranially into C57/BL6 mice and this model is
still commonly used today (Fig. 3) (201). Another mouse glioma cell line called GL261, also
derived from C57/BL6 mice, has similar characteristics to GL26 cells and both these cell
lines are useful for studying the response of brain tumors to immunotherapy (202). More
recently, other models have been developed, including a syngeneic glioma cell line derived
from spontaneous tumor in a transgenic mouse model called 4C8. These cells express GF AP
and the histology was densely cellular, and developed a pseudopallisading pattern of
necrosis. All these features are commonly found in human glioblastoma, making this a very
useful model for testing and developing novel gene therapeutic agents (203). Although these
models are useful in pre-clinical studies of anti -tumor therapies, the main focus has centered
on understanding the molecular pattern of gliomagenesis by altering genes believed to play
d RG2 cell lines.
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Figure 3 (See color insel1) C57/BL6 mice were challenged with 20000 GL26 cells injected into
the striatum. The animals were moribund after 25-30 days. (A) Nissel staining of a brain section
showing a GL26 tumor from an untreated moribund animal. Scale bars: 1000 J.l.m in low
magnification shots, 250 ~m in higher magnification shots. (B) GFAP immunostaining of a brain
section from an untreated moribund animal shows activated astrocytes. A higher magnification
picture shows infiltration of tumor cells into the surrounding CNS tissue. Scale bars: 1000 J.lm in low
magnification shots; 100 I1ID in higher magnification shots.
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an important role. Transgenics in particular have led to the development of a wide variety of
mouse models of glioma that are closer approximations of human disease.
Genetic Modelling of Glioma Formation
Researchers have aspired to develop mouse glioma models by deleting (knockout) or
inserting (transgenic) genes commonly mutated in human disease. The aim of this
approach is twofold. Firstly, a greater insight into the key factors contributing to
gliomagenesis and disease progression can be elucidated from these studies. This may lead
to the identification of key targets for gene therapy or more conventional drugs. Secondly,
more accurate pre-clinical models of the human disease should improve the process of
drug testing and development for treating glioma. Recently, a number of mouse strains
have been developed that mimic many of the histological and pathological features of
human gliomas. Furthermore, many of these models consistently give rise to brain rumors
that strongly resemble particular classes or types of human glioma. These models have
enormous potential for understanding the different genetic alterations and cellular
precursors of glioma tumors and in refining novel tllerapies, including gene therapy, in a
relevant pre-clinical model. In this section we will discuss the recently developed and most
promising models of glioma.
Transgenic Mouse Models of Glioma
Two transgenic mice in particular have proved very useful in the study of gliomagenesis
and have also been used to evaluate glioma therapies. In these mice, the oncogenes v-src
and v12H-Ras have been introduced into murine germlines under the control of the GFAP
promoter. GF AP expression is confined to cells of the astrogliallineage and this regulation
is under control of the highly specific GFAP promoter. Consequently, the oncogenic
potential of v-src or v12H-Ras is also confined to astroglial cells in this model. One line
derived from v12H-Ras transgenic mice develop solitary tumors that closely resemble low
grade astrocytoma (grade ll), whereas animals homozy,gous for the transgene develop
multifocal tumors that represent anaplastic astrocytoma (grade ill). Similarly transgenic
mice expressing v-src under the control of GFAP promoter also develop tumors that
resemble human astrocytomas (grade ll) (204). Tumors in these models further develop
into grade ill tumors and ultimately to glioblastoma (grade IV). This order of events
closely follows progression of glioma in humans. Furthermore, tumors in v12H-Ras
transgenic mice displayed many molecular changes commonly associated with
glioblastoma in humans including elevated EGFR and MDM2 and CDK4 expression,
elevated AKT activity, and decreased levels of INK4A, ARF, and PTEN expression
(205,206). Additional mutations in tumor suppressor genes and proto-oncogenes have also
been developed and these in general accelerate the development of glioblastoma (206).
Consequently, these mice closely model glioma progression in humans and may be more
accurate indicators of gene therapeutic agents in pre-clinical studies.
Knockout Mouse Models of Glioma
In general, mutations in signal transduction pathways regulating the cell cycle or RTK
activity are evident in many if not all gliomas and playa fundamental role in the
progression of the disease. Of the many mouse strains developed with mutations in genes
commonly altered in human glioma, only germline deletion of the tumor suppressor genes
p53 and NFl alone was found to increase the susceptibility of mice to astrocytoma and
glioblastoma (207). This supports the work of others suggesting that p53 mutation or
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wide variety of deletion is a very early event in gliomagenesis (11). INK4A and ARF have also been
studied as regulators of gliomagenesis. Although deletion of either or both gene products
alone is not sufficient to induce glioma formation in mice, somatic transfer of the RTK
PDGF into astrocytes and nestin-producing CNS progenitor cells greatly enhances the
appearance of mixed oligoastrocytomas and oligodendrogliomas, respectively (208). This
supports the conclusions of others that disregulation of the cell cycle induces a change in
phenotype of glioma from slowly proliferating grade II to rapidly proliferating grade ill
tumors. However, initial growth factor independence is required to promote
gliomagenesis (27).
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Clinical trials are scientifically designed experiments to determine how efficient new
treatment modalities would affect disease outcome and progression in human patients.
Many therapeutic formulations can be used in clinical trials such as chemotherapeutic
drugs, surgical procedures or gene therapy. The majority of brain tumor clinical trials
involve radiation therapy or chemotherapy. There are three different phases (Phase I,
II, ill) that clinical trials must encompass in order to answer all the needed research and
therapeutic questions. Phase I trials determine the best treatment schedule and the best
dose of treatment and importantly the safety of the proposed treatment. The effect of the
treatment on the actual brain tumor is not the primary issue while safety, dosage, and side
effects are. A small trial size is used due to the uncertainties. Phase II trials determine the
effect of the treatment on the brain tumor (i.e., does the tumor size shrink?). A safe dosage
has been established in Phase I so investigating the anticancer effect is the primary goal.
Phase ill trials compare the new treatment to already existing treatments. A much larger
trial size is used in phase ill trials because these are proposed as established treatments
that will help reduce the tumor size and prolong patients' life span. There are definite
benefits to being a part of a clinical trial. Even if patients do not get selected for receiving
the new treatment, they will still receive the best possible treatments for brain
cancer available.
Table 2 summarizes the advantages and benefits of gene therapy vectors that already
tested in clinical trials. One of the main gene therapy approaches that have been
implemented in clinical trials is the use of the herpes simplex virus gene for HSVI-TK as a
conditional cytotoxic strategy. The gene is expressed in all infected cells, but it will only
cause cytotoxicity in the presence of the prodrug, GCV, in dividing, tumor cells and it will
not affect non-dividing, normal brain cells. After patients are administered the HSVI-TK
gene encoded withing a viral vector, they are given the antiviral drug, GCV. The HSV1-
TK gene product phosphorylates GCV and intraceUular kinases convert it to GCV
triphosphate that intercalates in replicating DNA causing cell death. Most of the clinical
trials using HSVI-TK and GCV have provided positive data for the outcome of brain
tumor patients (209-211). The intratumoral injection of retrovirus-packaging cells as well
as adenoviruses encoding HSV 1- TK followed by GCV administration has been tested for
glioma treatment in Phase I/II clinical trials (213,214). Human glioma cells express CAR
and integrin a;V on their cell surface, which mediate adenoviral attachment and
internalization, therefore making Ad attractive vectors for GBM gene therapy approaches
(Fig. 4). Both therapies were well tolerated and safe (152,212,213), with adenoviral
vectors encoding TK observed to be more efficient than retrovirus vectors, based on tumor
re-growth three months after gene therapy and extended glioma-bearing patients' survival
(212). Also, since delivery of retrovirus vectors is achieved by implantation of xenograft
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Table 2 Gene Therapy Vectors Tested in Clinical Trials for Glioma Treatment
Viral vectors Therapeutic effect Advantages Disadvantages
.Retrovirus
(Virus producing
cells)
.HSVI-TK: apop- .Antitumor effect
tosis
.IL-2/HSYI-TK:
apoptosis and
antitumor immune
response
.Survival rate
increase
.Low tumor
transduction
.Low immune
response against
the vector
.No systemic/local
adverse effects
.HSVI-TK; apop- .High transduction
tosis efficiency
.Adenovirus
(replication-
defective)
.Low diffusibility
.p53: apoptosis .Antitumor effect
.Immune response
against the vector
.Survival rate
increase
.No systemic/local
adverse effects
.Antitumor effect.Replicating
vectors ONYX-O15
(adenovirus) G207,
HSVl716
(Herpesvirus)
Newcastle disease
v;nl~
.Replication in
tumoral cells
selective cell lysis
.Immune response
against vectors
.Low recurrence
.Survival rate
increase
.No systernic/local
adverse effects
virus-producing cells rather than the retrovirus (152), this approach adds the hazards of
xenogeneic transplant rejection, absent in adenoviral-based therapies. A recent Phase ill
clinical trial compared the efficacy of HSVI-TK delivery using adenoviral gene therapy
with standard care of glioma patients, consisting of radical excision followed by
radiotherapy (214). The intracranial injection of the adenoviral vector encoding HSV1- TK
followed by the intravenous administration of ganciclovir (GCV) increased the survival
time of glioma from 40 to 70 weeks, without adverse side effects (214). In summary,
intratumoral adenoviral delivery ofTK, combined with GCV is a potential new treatment
for operable primary or recurrent high-grade glioma.
Phase I trials consisting in the intratumoral injection of an adenoviral vector to
deliver the p53 gene in glioma cells have also led to interesting results. The toxicity of this
treatment was minimal and there was no evidence of systemic viral dissemination. The
adenoviral p53 trial showed that exogenous p53 was expressed in the nuclei of glioma
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Figure 4 (See color insert) Expression of adenoviral receptors in human glioma cells. (A) The
coxsackie-adenoviral receptor (CAR) and (B) Integrine aV [!NT] expression were detected in U251
and U8? cells by immunofluorescence. Left panels show nuclei stained with DAPI and right panels
show the expression of the receptors using indirect immunofluorescence.
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cells and activated a downstream pathway that induces apoptosis and prevents the tumor
from expanding (20). The only downfall of this therapy was that the trans gene expression
was not widespread and therefore only the tumor cells close to the injection site were
killed. Further work to enhance the distribution of the therapeutic gene will increase the
possibilities of this therapy considerably.
A recent phase I clinical trial has been conducted to determine the safety of
ONYX-015, a mutated adenovirus that is able to replicate selectively in and kill tumor
cells, but not normal cells (215,216). The dose-escalation trial showed intra-cerebral
injections of ONYX-015 to be very well tolerated by glioma-bearing patients without any
adverse side effects attributable to the viral vector, even at doses as high as 1010 pfu (217).
Although therapeutic efficacy of all these novel gene therapy approaches will have to
await larger trials, they provide a solid scientific rationale for additional studies of
adenoviral-based gene therapy for brain tumors.
Replicating herpes simplex viral (HSV) vectors have also been used as replication
competent vectors to treat brain tumors in clinical trials. HSV -G207 vector contains two
mutations within the virus that confer specificity of G207 for dividing in tumoral cells,
while intact HSVI-TK gene provides a mechanism to control any herpetic infection that
may arise from use of these replicating vectors. In phase one clinical trials with G207 was
intratumorally injected in patients with progressive or recurrent glioma (218). MTD was
not established as the highest level 3 X 109 pfu was well tolerated and no herpetic,
encephalic or inflammatory effects were observed. Although one patient seroconverted,
exhibiting serum antibodies anti-HSVl after treatment, no systemic toxicity attributable to
G207 treatment was observed. Four patients survived at the end of the trial, while the mean
survival from diagnosis to death increased to 15.9 months.
Another replicating HSV vector, HSV1716, showed to be unable to replicate in
neurons while replicates and lyses glioma cells. In a phase one clinical trial, HSV1716 was
intratumorally injected in glioma patients. The MTD for this vector was not determined as
up to 1 X 105 pfu were tolerated well with no encephalitis or herpetic complications, all
patients remaining seronegative for HSV-l (219). In an additional trial, recurrent patient
tumors were examined after injection of HSV1716 and virus was detectible by
lOViral vector to
le toxicity of this
;semination. The
rluclei of glioma
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semiquantitative PCR (220). Even in inoculated tumors for which virus was not detectible,
reinfection in vitro triggered low level HSV 1716 viral shedding indicating persistent long-
term effects may be possible (221). HSVl716 was also intracranially injected after glioma
resection to eliminate residual tumor cells (222). Of 12 patients, three survived, one died of
non related events, and eight died after tumor progression. No treatment related toxicities
were observed. Further clinical trials are ongoing.
Replication-competent Newcastle disease virus (NDV) has also been used in clinical
trials. Glioma tumor cells taken from patients were infected with NDV, irradiated, and
used to vaccinate the patient, who survived significantly longer than non-vaccinated
controls and the therapy was well tolerated (223,224).
Several clinical trials have been testing the potential of chimeric toxins targeting
receptor that are overexpressed in human gliomas. Clinical trials testing the antitumoral
potential of the intratumoral administration of IL-13 toxin, consisting in IL-13 fused to
Pseudomonas exotoxin, are currently being developed in the United States, Canada,
Germany, Israel, and the Netherlands. In a PhaseI/Il clinical trial, patients with
glioblastoma multiforme were intratumorally injected with IL-13 toxin eight days before
surgical resection (225). Necrotic areas were found in the tumors from half the patients,
suggesting that the toxin successfully induced tumoral cell death.
The chimeric toxin composed of IL-4 and Pseudomonas exotoxin was intracranially
administered to patients with recurrent glioblastoma multiforme in Phase I and Phase I/II
clinical trials. The intratumoral administration of 1L-4 cytotoxin showed an acceptable
safety profile, being well tolerated at low doses (226). These studies suggested that this
cytotoxin has anti-tumor activity, inducing necrosis in the tumor parenchyma, without
histological evidence of toxicity to normal brain tissues (227). Although local toxicity,
such as intracranial edema, was reported, it seems to be due to tumor necrosis or
occasionally to the volume of infusion.
Transferrin-diphteria toxin was locally administered by high-flow interstitial
microinfusion to patients with recurrent malignant brain tumors, which were refractory
to conventional therapy (179). Although episodes of local toxicity in some of the patients
were reported, direct interstitial infusion was shown to successfully distribute the toxin in
the tumor and infiltrated brain areas, achieving anti-tumor responses without severe
neurologic or systemic toxicity (228).
A chimeric toxin consisting of TGF and Pseudomonas toxin was tested in a Phase I
trial to determine its dose limiting toxicity. The chimeric toxin was determined by
convection-enhanced elivery in 20 patients with recurrent malignant brain tumors. In this
trial the maximal tolerated dose could not be established, being the overall median survival
23 weeks after intracranial administration of the toxin (229).
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